1. A method of treating, stabilizing and / or preventing ocular disorders, the method comprising administering a therapeutically effective amount of an anti-C5 agent in combination with an anti-PDGF agent to a subject in need thereof, the anti-C5 agent being a pegylated or non-pegylated aptamer that binds to C5 complement. 2. The method of claim 1, wherein the pegylated or non-pegylated aptamer has a sequence selected from: SEQ ID NO: 1 through 69, 75, 76, 81, 91, 95, and 96.3. The method according to claim 1, where the pegylated or non-pegylated aptamer has the sequence of SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 67.4. The method according to claim 1, where the anti-C5 agent is a pegylated aptamer having the structure indicated below or its salt: where it indicates fC and fU = 2 '- fluorine nucleotides on the linkerg, and mG and mA = 2' - OMe nucleotides and all other nucleotides are 2'-OH, and 3T indicates inverted deoxythymidine. 5. The method of claim 4, wherein the linker is an alkyl linker. The method according to claim 5, where the alkyl linker contains from 2 to 18 consecutively located CH groups. The method of claim 1, wherein the anti-C5 agent is a pegylated aptamer having the structure shown below: where fC and fU = 2 ′ are fluoronucleotides, and mG and mA = 2 ′ are OMe nucleotides and all other nucleotides are 2'-OH , and where 3T indicates inverted deoxythymidine. 8. A method according to any one of the preceding claims, wherein the ocular disorder is macular degeneration or diabetic retinopathy. The method of claim 8, wherein macular degeneration is age-related macular degeneration (AMD). The method according to claim 9, where age-related macular degeneration (AMD) is1. Способ лечения, стабилизации и/или профилактики глазного нарушения, при этом способ включает введение терапевтически эффективного количества средства против С5 в комбинации со средством против PDGF субъекту, нуждающемуся в этом, причем средство против С5 является пегилированным или непе
